The representation of Saudi women in Al-Jazirah and BBC Arabic: corpus-based critical discourse analysis

In Saudi society, the role of women is less compared to men. Male domination constantly remains in various fields and women often marginalised in societies. Saudi women are often portrayed as wearing hijab (veil), being mother and wife. Their involvement is merely limited to family matters, women activities, and social affairs. This study examines the way modern standard Arabic online news of Al-Jazirah of Saudi Arabia and BBC Arabic of United Kingdom represent Saudi women in their news reports between 2010 and 2014. The main aim of this study is to discover how Saudi women are represented in these two prominent online news outlets by analysing the ways language is strategically used by Al-Jazirah and BBC Arabic to portray Saudi women. The study will be conducted in the form of Corpus investigation with data being gathered from news archives and then analysed using AntConc software. The research employs Critical Discourse Analysis approaches of van Leeuwen and Fairclough with the help of Corpus analysis techniques. The study finds differences between Al-Jazirah and BBC Arabic representation of Saudi women at both the textual and discursive levels. Also, the analysis reveals that the two outlets practised group polarisation characteristics. The in-group in Al-Jazirah coverage are the Saudi women and the Saudi authorities; hence the outlet produced hegemonised discourse and sustained the government policies. In comparison, the in-group in BBC Arabic is the women activists who criticise the government policies of women. It is recommended that the future study on the representation of Saudi women in the media inquire further into said problems and limitations, to get into a more comprehensive understanding of media coverage of women in Saudi Arabia. The preliminary result of the study shows that both news institution has a different way of portraying Saudi women according to their political agenda and ideologies. Thus, at the end of this study, the researcher hopes to reveal the representation of Saudi women in BBC Arabic and Al-Jazirah online news over the five years under the reign of King Abdullah

Verbal processes in the Covid-19 news discourses: An analysis of ‘aswaqpress.com’ coverage on Malaysia: Proses verbal dalam wacana berita Covid-19: Analisis portal ‘aswaqpress.com’ berkaitan Malaysia

December 2019 marked the emergence of a deadly virus known as Covid-19. Since then, we have been battling the virus, which has infected more than 250 million people and killed 4.5 million globally. The pandemic has become the headline of almost every media outlet, local and international news agency. Hence, this article aims to examine the Arabic online news discourse of the event by focusing on the verbal processes strategically utilised in reporting the pandemic in Malaysia. This study's data consists of Modern Standard Arabic online news published by Aswaq (aswaqpress.com) news portal between January and July 2021. Aswaq provides Arabic news and information on Malaysia to the Arab world. Hence, the information provided by the portal is vital in portraying Malaysia to Arab audiences, particularly in framing the way Malaysia deals with the Covid-19. The study employs corpus linguistics analytical tools using corpus software AntConc 3.5.8 (2019). Then, the quantitative result will be analysed using a qualitative approach based on the textual-oriented Critical Discourse Analysis (CDA) of Fairclough (1992). It is shown that Aswaq has strategically utilised various verbal processes to report on the word said and articulated around the pandemic. The diversity of verbal processes usage indicates different connotations that hint at different strategic approaches in reporting the news. Hence, it may lead to uncovering the outlet stance of the event. Finally, the study will present suggestions for other related studies in the future

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc